

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 79998

Title: COVID 19 and liver: Are footprints still there?

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00000663 Position: Peer Reviewer Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: Italy

Author's Country/Territory: India

Manuscript submission date: 2022-09-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-09-14 13:36

Reviewer performed review: 2022-09-20 12:46

Review time: 5 Days and 23 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com **https:**//www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The study reviews the relationship between COVID-19 infection and outcomes in relation to liver disease, under different aspects, from pathophysiology of infection to liver disease response. Overall, data are interesting, giving a broad view of what was published in the last 2 years on this relevant topic and preparing for the future. I have a few issues that should be considered: 1) The authors are invited to report how they retrieved and selected the literature 2) The role of ACE receptor and treatment should be better clarified, considering the extensive discussion in the beginning of pandemia. The manuscript would take great advantage of a picture detailing the various aspects involved in this tricky relationship. 3) The chapter of COVID-19 and Liver cirrhosis largely duplicates the one of Chronic liver disease and COVID-19 – in a few cases, same wording. I would greatly suggest to have them merged in a single chapter. 4) Always quote COVID in capital letters 5) COVID-19 and Liver Cirrhosis: the first line is missing something 6) COVID-19 and Autoimmune hepatitis: first line should start as "Very little...."



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 79998

Title: COVID 19 and liver: Are footprints still there?

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05744914 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Russia

Author's Country/Territory: India

Manuscript submission date: 2022-09-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-09-14 15:13

Reviewer performed review: 2022-09-22 16:13

Review time: 8 Days and 1 Hour

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com **https:**//www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

1. On page 1, in "Approximately 15% of patients will eventually have respiratory compromise..." the word "will" should be changed to "would"; 2. "SARS-CoV2" and/or "SARS COV-2" should be unified throughout the text; 3. Please explain shortly what the ACE2 protein/receptor is and where it is expressed somewhere close to the very beginning of the SARS-CoV2 hepatotropism section; 4. Abbreviations like ULN, IL, TNF, GI, etc. should be expanded whenever they occur in the text for the 1st time; 5. On pages 5/6, "The tocilizumab" should be changed to "Tocilizumab" 6. On page 7, kindly please provide some references for the line "Multiple lines of evidence, such as findings from international registries, sizable observational cohorts, and population-level data, have all been used to support this"; 7. On page 9, kindly please provide some references for "...intestinal permeability and dysbiosis linked to cirrhosis..."; 8. I would recommend moving the paragraph about how "it is still unclear how the highly frequent Omicron variation affects patients with CLD and cirrhosis" somewhere higher, closer to the beginning of the review (as some kind of a disclaimer); 9. On page 11, "to have drank" should be changed to "to have drunk"; 10. On page 13, please clarify "SARS and CoV-2" infections"; 11. Are there any studies dealing with whether different stages of N/MAFLD (i.e., steatosis, steatohepatitis, fibrosis) differentially affect the course and/or outcomes of COVID-19? If so, please clarify shortly; 12. On page 14, "A very little" should be changed to "very little"; 13. On page 15, kindly please provide some references and/or supporting evidence for "Possibly these persistent antigens cause immune dysfunction and low-grade persistent inflammation"; 14. On page 15, please rewrite "Effects of COVID Already mRNA vaccines" for clarity; 15. I would suggest expanding the conclusion a bit so as to include the information on which liver disease



has the most impact on the course/and or outcomes of COVID-19, and vice versa, etc. I would also recommend shortly mentioning further research directions in Conclusion; 16. Please rescale Figure 1 so as to avoid the disruption of long words, e.g. "Dysregulate_d", etc. Also, "underlaying" should be changed to "underlying".

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 79998

Title: COVID 19 and liver: Are footprints still there?

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00000663 Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: Italy

Author's Country/Territory: India

Manuscript submission date: 2022-09-13

Reviewer chosen by: Yu-Lu Chen

Reviewer accepted review: 2022-10-24 09:55

Reviewer performed review: 2022-10-24 10:07

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good
	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish



Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

No Comment